Medical/Pharmaceuticals
Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
TOKYO, May 11, 2023 /PRNewswire/ -- Nippon Express Italia S.p.A. (hereinafter "NX Italia"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association...
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin
MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin. Turn Bio's...
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
* Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapyin Europe * IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS, May 10, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group...
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
Gencurix announced Korean and Japanese cancer patients' 15-year follow-up prognostic test clinical results
SEOUL, South Korea, May 9, 2023 /PRNewswire/ -- Gencurix
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
* This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID * Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators * For the stand-alone influenza vaccine candid...
3 in 5 people Have Side Job to Help Make Ends Meet - Herbalife Asia Pacific Survey
SINGAPORE, May 9, 2023 /PRNewswire/ -- Herbalife, a global health and wellness company and community, released the findings of its 2023 Asia Pacific Side Job Survey which showed that almost 3 in 5 (59%) respondents have a side job, and the top reason for doing so is to make ends meet (61%). Other...
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE
SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), i...
CIVCO Radiotherapy and Qfix Showcase as One Company at ESTRO 2023
CORALVILLE, Iowa, May 8, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix, now together as one company, will exhibit their innovative and patented solutions during the annual ESTRO Congress inVienna, Austria, 12-16 May 2023. The company encourages attendees to visit booth #200 to experience many ...
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease * Data presented shows preclinical proof of concept for HMBD-011 clearance of VH4-34+ antibodies and effective inhibition of col...
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...
Bolivian and Taiwanese Experts Discuss the Latest Med-Tech Developments to Position Bolivia as a Leading hub in Robotic Neurosurgery
HSINCHU, May 8, 2023 /PRNewswire/ -- Medical experts from Bolivia and Taiwan recently joined forces to explore the latest technological advancements in surgical navigation robots and their potential to positionBolivia as a leader in robotic neurosurgery. During the largest robotic surgery online ...
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A inEurope. Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show th...
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Duoning Biotech Celebrates Ground Breaking for Its Global Headquarters
SHANGHAI, May 8, 2023 /PRNewswire/ -- On May 6th, the "2023 Commencement Ceremony for Major Industrial Projects in Fengxian and for Duoning's Global Headquarters and Industrialization Base" was held grandly in the Biotechnology Park. Leaders of the Fengxian district, representatives of the Orient...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24